Music Therapy Emerging as a Trending Focus in Oncology Rehabilitation
On November 15, 2024, the "2024 China Integrative Oncology Conference's Tumor Music Intervention Sub-forum and the Second Academic Annual Meeting...
medical news
Eli Lilly’s Kisunla™ Receives U.S. FDA Approval for Treatment of Early Symptomatic Alzheimer’s Disease
On July 2, 2024, the U.S. Food and Drug Administration (FDA) approved Kisunla™ (donanemab-azbt, 350 mg/20 ml intravenous infusion once...
New treatment appears! Can late-stage cancer be cured with 4 million?
Even though it is known as the anti-cancer miracle drug, CAR-T therapy is not perfect. Even though it has brought...
Multiple clinical data for advanced solid tumors of Maiwei Biotech’s “9MW2821” will be announced soon
Introduction: 9MW2821 is Maiwei Biotech’s first site-specific conjugated ADC drug targeting nectin-4. Maiwei Bio announced that it will announce the...
New Research Shows Accelerated Aging Linked to Increased Cancer Risk in Younger Adults
Cancer rates among young people have increased in recent years, leaving researchers scrambling to understand why. A new study suggests...
$1.16 billion! Novartis wins AR PROTAC
On April 11, Novartis announced the establishment of an exclusive strategic partnership with Arvinas to jointly promote the research and...
Fumetinib mesylate is now recruiting at multiple centers across the country for lung cancer with EGFR exon 20 insertion mutations
There are currently three third-generation EGFR lung cancer targeting drugs that have been approved for marketing in China: osimertinib, ametinib,...
Why is the end of AI said to be biopharmaceuticals?
What is the end of AI? Some investors said it was photovoltaics, while others said it was electricity. The answer...
Hengrui Medicine’s “New Type 1 Psoriasis Drug” Receives Clinical Approval
ntroduction: Hengrui Medicine’s immune sector is expected to add another potential blockbuster drug. Today (March 29), according to the CDE...
The world’s first! Astellas Claudin18.2 monoclonal antibody approved in Japan
On March 26, Astellas announced that its Claudin18.2 antibody Zolbetuximab (Vyloy) was approved for marketing in Japan, and the approved...
Will sky-high-priced rare disease drugs be withdrawn from the market? Pharmaceutical companies respond: Special drug imports will be reintroduced into the country
The International Rare Disease Day has just passed, and the news that a rare disease drug will be withdrawn from...
JAB-30300, P53 Y220C activator, received IND approval in the United States
JACUS Pharmaceuticals (1167.HK) announced that its independently developed P53 Y220C activator JAB-30300 has been approved for new drug clinical trial...
